Catalytic Asymmetric Formal Insertion of Aryldiazoalkanes into the C–H Bond of Aldehydes: Synthesis of Enantioenriched Acyclic α-Tertiary Aryl Ketones
摘要:
A novel, catalytic enantioselective route to synthesize a variety of a-tertiary aryl ketones via a boron Lewis acid promoted formal insertion of aryldiazoalkane into the C-H bond of both aromatic and aliphatic aldehydes is described. In the presence of chiral (S)-oxazaborolidinium ion catalyst 1, the reaction proceeded in good yields (up to 94%) with excellent enantioselectivities (up to 99% ee).
The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
The present disclosure provides compounds that inhibit protein kinases, such as JAK, Axl, or Syk kinases, compositions comprising the compounds and methods of using the compounds to inhibit protein kinase and treat and/or prevent diseases associated with inappropriate kinase activity.
The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein: R
1
, R
2
, Z
1
, t, and ring A are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of JNK, such as diabetes, the method comprising administering to a mammal an effective amount of a compound of formula (I).
Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses
申请人:Li Hui
公开号:US20070299060A1
公开(公告)日:2007-12-27
The present disclosure provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.
The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.